Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

CSL (CSLLY) Stock Price & Analysis

CSLLY Stock Chart & Stats

$35.30$0.55(1.59%)
At close: 4:00 PM EDT
$20$25$3013 Jul27 Jul10 Aug24 Aug8 Sep16 Sep9 Oct
Day’s Range
$35.30 - $35.30
52-Week Range
$16.48 - $35.30
Previous Close
$34.75
Volume
316.37K
Average Volume (3M)
1,545
Market Cap
$67.74B
Enterprise Value
$48.96B
Total Cash (Recent Filing)
$1.51B
Total Debt (Recent Filing)
$10.90B
Price to Earnings (P/E)
―
Beta
0.28
Next Earnings
Feb 09, 2027 (Est.)
EPS Estimate
N/A
Last Dividend Ex-Date
Sep 10, 2026
Dividend Yield
2.02%

Bulls Say, Bears Say

Bulls Say

Resilient Cash Generation

Strong operating cash flow provides internally generated funding for research, manufacturing capacity, dividends, and buybacks. The 1.8x net-debt-to-EBITDA ratio also indicates that CSL can return capital while retaining meaningful financial flexibility for ongoing investment.

Transformation Savings

Savings delivered ahead of plan can create a more durable operating base if retained or selectively reinvested in commercial and R&D priorities. The multi-year program should support margins and competitiveness by lowering costs while preserving investment in growth areas.

Behring And Product Momentum

Growth from newer therapies and expected mid-single-digit Behring expansion strengthen CSL’s core specialty-biologics platform. Successful launches can diversify the portfolio, deepen physician and patient adoption, and help offset pressure in mature products over the next several quarters.

Bears Say

Large Impairments And Statutory Loss

The scale of impairments and the resulting statutory loss materially weaken reported earnings quality and the equity cushion. Although largely noncash, these charges signal that prior assets or investments underperformed, increasing uncertainty around capital allocation and future returns.

Structural Vifor Decline

Vifor’s combination of generic competition, reimbursement changes, price erosion, and product-access loss represents a structural rather than temporary drag. A forecast 25% revenue decline can reduce group growth, dilute mix, and require management to redirect resources toward replacement opportunities.

Albumin And Margin Pressure

Persistent pricing and market-value pressure in China is weighing on a major Behring product line and its margins. Even with a slower decline in the second half, continued albumin weakness can constrain profitability and limit the benefits from volume growth elsewhere in the portfolio.

CSL News

CSLLY FAQ

What was CSL’s price range in the past 12 months?
CSL lowest stock price was $16.48 and its highest was $35.30 in the past 12 months.
What is CSL’s market cap?
CSL’s market cap is $67.74B.
When is CSL’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CSL’s earnings last quarter?
CSL released its earnings results on Aug 17, 2026. The company reported -$1.561 earnings per share for the quarter.
Is CSL overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does CSL pay dividends?
CSL pays a Semiannually dividend of $0.391 which represents an annual dividend yield of 2.02%. See more information on CSL dividends here
What is CSL’s EPS estimate?
CSL’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CSL have?
CSL has 1,919,537,100 shares outstanding.
What happened to CSL’s price movement after its last earnings report?
CSL reported an EPS of -$1.561 in its last earnings report. Following the earnings report the stock price went up 17.042%.
Which hedge fund is a major shareholder of CSL?
Hedge funds hold CSL shares: the largest hedge-fund position in CSL is 62,325,120 shares, and hedge funds decreased their holdings by 66.1K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology